Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts
- 12 January 2007
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 14 (3) , 279-286
- https://doi.org/10.1038/sj.cgt.7701013
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Highly Efficient and Tumor-Restricted Gene Transfer to Malignant Gliomas by Replication-Competent Retroviral VectorsHuman Gene Therapy, 2003
- Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse modelsGene Therapy, 2002
- Genomic Stability of Murine Leukemia Viruses Containing Insertions at the Env-3′ Untranslated Region BoundaryJournal of Virology, 2001
- A Uniquely Stable Replication-Competent Retrovirus Vector Achieves Efficient Gene Deliveryin Vitroand in Solid TumorsHuman Gene Therapy, 2001
- Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the escherichia coli purine nucleoside phosphorylase geneHepatology, 2000
- Fortnightly review: Bladder cancerBMJ, 1998
- Constitutive production of multiple cytokines and a human chorionic gonadotrophin beta-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiationBritish Journal of Cancer, 1997
- Adenovirus-mediated suicide gene therapy for experimental bladder cancerUrology, 1997
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996